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Clinical Research Center, Karolinska University Hospital, Stockholm, SwedenIntroduction: Animal models of chronic kidney disease demonstrate that a redundant population of
therapeutically bioactive selected renal cells (SRCs) can be delivered to the kidney through intra-
parenchymal injection and arrest disease progression. Direct injection of SRCs has been shown to
attenuate nuclear factorkB, which is known to drive tissue inﬂammation, as well as the transforming
growth factorbmediated plasminogen activator inhibitor1 response that drives tissue ﬁbrosis.
Methods: We present experience from the ﬁrst-in-human clinical study with SRCs. Seven male type 2
diabetic patients (63  2 years of age) with chronic kidney disease stage 3 to 4 (estimated glomerular
ﬁltration rate 25  2 ml/min) were recruited. After blood and urine sampling, iohexol clearance, magnetic
resonance imaging, and renal scintigraphy, patients underwent ultrasound-guided renal biopsy. Two
cores of renal tissue were shipped to the manufacturing plant for cell isolation, culture, and product
preparation. Formulated SRCs were transported back to study sites (range 59–87 days after biopsy) for
intracortical injection using a retroperitoneoscopic technique.
Results: Laparoscopically assisted implantation of SRCs was uneventful in all patients. However, post-
operative complications were common and suggest that other techniques of SRC delivery should be used.
Kidney volume, split function, and glomerular ﬁltration rate did not change during 12 months of follow-up.
An extended 24-month follow-up in 5 of the patients showed a decline in estimated glomerular ﬁltration
rate (cystatin C).
Discussion: Postoperative complications following retroperitoneoscopic implantation of SRC in the kidney
cortex seem to be related to the surgical procedure rather than to injection of the cell product. No changes
in renal function were observed during the original 12-month protocol. Beyond the ﬁrst 12 months after
cell implantation, individual renal function began to deteriorate during further follow-up.
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estimated to be 8% to 16%, CKD is considered a public
health priority.1 Worldwide, the incidence and prev-
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International Reports (2016) 1, 105–113diabetes is today the most common cause of progressive
loss of nephrons, end-stage renal disease, and need for
renal replacement therapy in the western world.3 Un-
fortunately, human kidneys have a limited ability to
repair themselves, and renal progenitor cell activation
during renal repair is low.4 However, as CKD is char-
acterized by low kidney cell proliferation and loss of
regenerative processes,5 maladaptive responses and
ﬁbrosis lead to progression of CKD. Although standard
of care therapies, such as strict glycemic control and
blockade of the reninangiotensinaldosterone axis,105
CLINICAL RESEARCH P Stenvinkel et al.: Implantation of Autologous Selected Renal Cellsslow progression of diabetic nephropathy, they do not
arrest or reverse it. A number of novel treatment
strategies, such as antiproteinuric treatments, inhibitor
of sodiumglucose co-transporter 2, antiﬁbrotic
agents, endothelin receptor antagonists, or transcrip-
tion factors may slow or arrest the progression of dia-
betic kidney disease.6 In addition, as regeneration of
tissues and organs is now within the technological
reach of modern medicine,7,8 renal cellbased thera-
pies have recently attracted interest for clinical use.4,7
Although human renal progenitor cells over the last
decade have been shown to have a therapeutic effect in
various animal models of CKD,9,10 their use has been
limited by their constrained availability and low
nephrogenic potential. Their short lifespan and ten-
dency to become senescent over time also limit their
use.4 Studies on regeneration following acute kidney
injury suggest that tubular epithelial cells are central in
the restoration of renal function.11 As it has been
documented that the kidney tubular epithelium is
repaired by resident surviving epithelial cells12 in the
absence of progenitor cells,13 the possibility of
arresting progression by adult renal-derived cells may
be an attractive alternative. Animal studies of experi-
mental CKD show that implantation of intra-
parenchymal differentiated adult renal cells have
regenerative capacity while reducing ﬁbrosis and dis-
ease progression. In a rat model of CKD, human
primary kidney cells enriched with erythropoietin
(EPO)–positive cells improved chronic kidney injury.14
As few of the injected cells were detected after 12
weeks, the nature of the beneﬁcial effects observed
were likely paracrine. In a study of 5/6 nephrectomized
rats, Kelley et al.15 demonstrated that a tubular
cellenriched subpopulation of primary renal cells
improved survival and augmented kidney function. In
a study of rats with progressive diabetic nephropathy,
injection of a population of syngeneic selected renal
cells (SRCs) enriched with tubular cells stabilized dis-
ease progression and improved survival.16 Although
the exact mechanism(s) for the observed favorable ef-
fects are not evident, activation of genes involved in
regenerative processes, such as SOX2 and CD24, have
been reported to be operative.17 Moreover, recent data
in rodents suggest that the beneﬁcial effects of SRCs
were transmitted via nuclear factorkB and trans-
forming growth factorb1 pathways.18 Based on the
previous favorable experience with implantation of
renal cells in diabetic ZSF1 rats with progressive dia-
betic nephropathy,16 rodents undergoing 5/6 renal
mass reduction15 and normal mongrel dogs,19–21 the
primary objective of this ﬁrst in-human, 2-center,
open-label, single-group study was to assess the safety106of implantation of expanded autologous SRCs (100 
106 cells/ml) formulated in a gelatin-based hydrogel
directly in the renal cortex. The secondary objective of
the protocol was to assess the effects of SCR on renal
function after a 12-month observation period. We also
present data on 24-month follow-up in 5 of the
patients.
MATERIALS AND METHODS
Seven adult, male, type 2 diabetic, CKD stage 3 to
4 patients at the Department of Renal Medicine,
Karolinska University Hospital, Stockholm, Sweden
(n ¼ 6) and Department of Renal Medicine, University
of North Carolina at Chapel Hill, North Carolina, USA
(n ¼ 1) were recruited for the study. No female type
2 diabetic CKD stage 3 to 4 patients agreed to partic-
ipate. The study was approved by the regional com-
mittees of ethics in Stockholm and Chapel Hill and
adhered to the statutes of the Declaration of Helsinki.
All patients provided written consent to participation.
A detailed list of inclusion and exclusion criteria is
listed in the Supplementary Material online. In short,
adult (30–70 years of age), type 2 diabetic patients
with GFR 15 to 50 ml/min and clinical course
compatible with diabetic nephropathy, ongoing
angiotensin-converting enzyme inhibitor/angiotensin
receptor blocker treatment and a kidney size >10 cm
(cortical thickness >5 mm) were eligible for inclusion.
Patients who satisﬁed the eligibility criteria and pro-
vided signed informed consent entered a screening
phase including full physical examination, electrocar-
diography and laboratory assessments (hematology,
serum chemistry, and urinalysis). Magnetic resonance
imaging (MRI) was performed to assess kidney volume
and cortex thickness. Renal scintigraphy was per-
formed to assess split kidney function and iohexol
clearance to estimate GFR. Eligible patients underwent a
kidney biopsy according to the standard clinical pro-
cedure (2 cores) to obtain autologous cells for implan-
tation. The study protocol is depicted in Figure 1. The
protocol was approved by both the Food and Drug
Administration and the Medical Products Agency
(MPA)Uppsala, Sweden. The clinical trial (clinicaltrials.
gov) number is NCT02008851.
Cell Preparation
Neo-Kidney Augment (NKA) is an injectable product
that is currently being investigated to treat CKD in
clinical trials. NKA is a cell therapy composed of
autologous SRCs formulated in a gelatin-based hydro-
gel. NKA is manufactured by ﬁrst obtaining a kidney
biopsy sample from the patient at the clinical site,
which is shipped in cell culture medium (Dulbecco’sKidney International Reports (2016) 1, 105–113
Screening
Assessments
(Renal Dept)
Biopsy
(Renal Dept)
ImplantaƟon
(TransplantaƟon
Dept)
Follow-up
• Obtain Informed Consent
• Review Inclusion/Exclusion Criteria
• Iohexol clearance
• Imaging Studies (MRI, renal scintigraphy) 
• Admit to hospital 1 day before
• Collect two cores of kidney tissue for shipment to cell lab 
• Discharge from hospital one day after
• Day -1: Admit to hospital
• Day 0: Implant
• Day 1: Safety Assessments
• Day 2-4: Discharge at discretion of PI
• Days 7, 14, and 28 (Transplantation)
• Months 2, 3, 4, 6, 12, 24 (Renal Dept)
• Conduct screening assessments
Figure 1. Simpliﬁed ﬂow schedule of the protocol. MRI, magnetic resonance imaging.
P Stenvinkel et al.: Implantation of Autologous Selected Renal Cells CLINICAL RESEARCHmodiﬁed Eagle’s medium, obtained from Thermo Fisher
(Waltham, MA), at 4C to the manufacturing site).
Because the whole kidney biopsy material is needed for
cell preparation histology, molecular analysis of kidney
specimen is not performed. Aseptic procedures are
conducted in Class 100 Biological Safety Cabinets (BSC).
The cell culture-processing core consists of 2 produc-
tion suites and an adjacent incubator room validated to
Class 10,000 (ISO 7) standards. One Class II Type A2
(Class 100, ISO 5) biological safety cabinet is located in
each production suite for tissue processing and cell
culture operations. All patient samples are handled in
individual production suites to provide temporal
segregation during processing. The production support
areas (media/materials staging, clean staging, etc.) are
designed to Class 100,000 (ISO 8) standards. All open
tissue processing and cell culture operations are per-
formed within Class II Type A2 (Class 100, ISO 5) BSC
using an aseptic technique. The preparation of SRCs
from patient biopsy samples has been previously
described in detail15,16,22,23 and is provided in the
Supplementary Material. A detailed description
of markers of the injected cells is provided in the
Supplementary Material.Kidney International Reports (2016) 1, 105–113Implantation Procedure
In the Swedish patients (patients 1–6), a Pfannenstiel
incision was made and a hand-assist device was placed
in the wound (Gelport, Applied Medical Resources
Corporation). Moving the peritoneum medially by
blunt manual dissection created a retroperitoneal
space.24 Gas pressure was kept at a maximum of
12 mm Hg. The medio-anterial portion of Gerota’s
fascia of the left kidney was opened to expose the peri-
renal fatty tissue, which was abundant in all cases. The
fatty tissue was removed to expose the kidney capsule,
essentially all of the medial and lateral aspects as well
as almost the entire convex/lateral part of the kidney.
The dissection allowed positioning of the kidney in
alignment with the injecting needle and visualizing
whether there was any penetration or leakage of the
injected material. From the left iliac fossa, a guiding
cannula was inserted transcutaneously to puncture the
kidney capsule at the lower pole. An 18-gauge needle
was thereafter inserted through the guiding cannula
into the renal cortex along the convex longitudinal axis
of the kidney. The SRC concentration per milliliter of
delivered NKA is 100  106 cells/ml, and the dosing
volume is set at 3 ml for each 100 g of kidney weight,107
Figure 3. Changes in magnetic response imaging (MRI) after 3
months. MRI was conducted at screening and after 3, 6, and 12
months, respectively. Exclusion criteria for participation included
major cysts, kidney size <10 cm, and cortical depth <0.5 cm at the
implantation site (upper dorsal part of the kidney). (Upper panels)
Size measurements were done on 4-mm-thick T2 weighted Haste
images. (Lower panels) Volumetry was performed on 2.5-mm-thick
T1 VIBE images. Note the difference in perirenal fat dorsal to the left
kidney before and after surgery, caused by the extensive dissection
to align the kidney with the needle at implantation. No scars or
remaining hemorrhage were apparent following renal cell
implantation.
CLINICAL RESEARCH P Stenvinkel et al.: Implantation of Autologous Selected Renal Cellswhich was estimated from the results of the MRI study
performed on or shortly after the screening visit. A
2-ml quantity of NKA was deposited at 4, 3, 2, and
1 cm from the puncture of the capsule over a 10- to
15-minute time period (total 8 ml) (Figure 2). The needle
was kept in place for 5 minutes to promote hemostasis.
No per-operative bleeding and only minimal amounts of
NKA (<1 ml) was observed backing out of the puncture
hole in any of the procedures. The ports were removed
under direct vision to detect any bleeding from the port
sites. The wound was not drained, and the abdominal
wall was closed with a running suture. In the US
patient, the surgical technique for implantation differed
(Supplementary Material).
Magnetic Resonance Imaging
Both before implementation (<30 days) and 3 and 6
months postimplantation, MRI was performed using a
1.5-T MR unit (Siemens Magnetom Aera, Siemens AEG,
Erlangen, Germany). Cortical thickness was measured
in the dorsal part of the upper pole of the kidney
(Figure 3) using a 4-mm-thick axial T2 Haste image.
The kidney volume was quantiﬁed by manual seg-
mentation using a dataset of breath hold 2.5-mm-thick
VIBE images obtained without fat saturation.
Renal Scintigraphy
Kidney function was evaluated in the supine position
3 hours after i.v. injection of 50 MBq 99mTc-DMSA (CIS
bio international, Gif sur Yvette Cedex, France). AnFigure 2. Selected renal cell (SRC) implantation procedure. The
extensive dissection allowed positioning of the kidney in alignment
with the injecting needle and visualizing whether there was any
penetration or leakage of the injected material. From the left iliac fossa,
a guiding cannula was inserted transcutaneously to puncture the
kidney capsule at the lower pole. An 18-gauge needle was thereafter
inserted through the guiding cannula into the renal cortex along the
convex longitudinal axis of the kidney. A 2-ml quantity of selected renal
cells was deposited at 4, 3, 2, and 1 cm from the puncture of the
capsule over a 10- to 15-minute time period (total 8 ml).
108anterior and posterior acquisition with a preset time of
20 minutes using a double-headed gamma camera
(Symbia T16 SPECT/CT, Siemens, Erlangen, Germany)
equipped with a low-energy, high- resolution colli-
mator, 256  256 matrix. Differential renal function
was assessed using region-of-interest drawings
including the entire kidney, with a geometrical mean
calculated from both projections.
Biochemical and Other Analyses
Analyses of high-sensitivity C-reactive protein, creati-
nine, cystatin C, iohexol clearance, hemoglobin, albu-
min, Ca, PO4, and albumincreatinine ratio (ACR) were
performed with validated routine methods at the
accredited Clinical Laboratory of Karolinska University
Hospital, Stockholm, Sweden and University of North
Carolina Hospitals, Chapel Hill, North Carolina, USA.
Statistical Analyses
Data are expressed as mean  SEM. Statistical signiﬁ-
cance was set at the level of P< 0.05. Comparisons over
time were assessed by the Student t test.
RESULTS
Patient Characteristics
Demographic and clinical characteristics along with
status at 24-month follow-up of 7 patients undergoing
implantation with SRCs are shown in Tables 1 and 2.Kidney International Reports (2016) 1, 105–113
Table 1. Clinical characteristics of patients undergoing selected
renal cell implantation
Patient NKA date Age (yr)
BMI
(kg/m2)
ESA
(IU/kg/BW)
SBP
(mm Hg)
DBT
(mm Hg)
1 22 Aug 13 64 28.7 0 136 81
2 04 Sep 13 53 35.7 0 155 82
3 14 Nov 13 68 37.3 69 148 66
4 28 Nov 13 67 28.6 0 140 70
5 12 Dec 13 70 29.5 117 167 79
6 25 Sep 14 62 29.6 0 120 70
7 25 Apr 14 57 38.5 0 134 82
63  2 32.6  1.7 143  6 76  3
Data are mean  SEM.
BMI, body mass index; DBP, diastolic blood pressure; ESA, erythroid-stimulating agents;
IU/kg/BW, international units per kilogram of body weight; NKA, neo-kidney augment;
SBP, systolic blood pressure.
P Stenvinkel et al.: Implantation of Autologous Selected Renal Cells CLINICAL RESEARCHThe patients’ basal renal functions are shown in
Table 3. The longitudinal individual changes in
S-creatinine, estimated glomerular ﬁltration rate (eGFR)
(cystatin C), glomerular ﬁltration rate (GFR) (iohexol
clearance), and ACR following SRC implantation are
shown in Figure 4.
Changes in Renal Function
Although no signiﬁcant differences between screening
S-creatinine (235  18 mmol/l) versus S-creatinine at
6 months (271  89 mmol/l; P ¼ 0.349), 12 months
(307  41 mmol/l; P ¼ 0.127), and 18 months (297 
27 mmol/l; P ¼ 0.120) were observed, a signiﬁcantly
higher S-creatinine level (339  35 mmol/l; P ¼ 0.048)
was observed 24 months after implantation in 5
patients. Compared to screening eGFR (25  2 ml/min/Table 2. Comorbidity at screening, serious adverse events (SAEs),
and clinical status at 24-month follow-up
Patient
Comorbidity prior to
implantation
SAEs during
observation period
Relationship
to NKA
Status at 24-month
follow-up
1 Stroke, lymphoma Pneumonia
and fatigue
Possible Myocardial
ischemia
and heart
failurea
2 None Fatigue and
postoperative
wound infection
Not related Chronic
obstructive
pulmonary
disease
3 BPH, peripheral
arterial
insufﬁciency
Urinary tract
infection and
ﬂuid retention
Not related Urinary tract
infections,
TUR-P
4 Stroke, TIA Fatigue Not related BPH, inguinal
hernia
5 Cox arthrosis,
stroke, cardiac
arrhythmia
Cecal volvulus
and anastomotic
hemorrhage
Not related Erosive gastritis,
constipation
6 Foot ulcer No SAE reported Doing wellb
7 Sleep apnea,
hyperlipidemia
No SAE reported Myocardial
ischemiac
BPH, benign prostatic hyperplasia; NKA, neo-kidney augment; TIA, transient ischemic
attack; TUR-P, transurethral resection of prostate.
aDeath due to cardiac failure 30 months after implantation.
b12-Month control.
c18-Month control.
Kidney International Reports (2016) 1, 105–1131.73 m2), eGFR tended (20  2 ml/min/1.73m2;
P ¼ 0.08) to be lower at 12 months of follow-up. In
5 patients who completed 24 months of follow-up,
eGFR was signiﬁcantly lower (13  5 ml/min/1.73 m2;
P ¼ 0.006) than in the screening phase. Iohexol clear-
ance at screening (26  3 ml/min/1.73 m2) did not differ
from iohexol clearance at 6 months (25  3 ml/min/1.73
m2; P ¼ 0.981) or 12 months (23  4 ml/min/1.73 m2;
P ¼ 0.658) after cell implantation. Compared to ACR at
screening (198  46 mmol/mol), no signiﬁcant differ-
ences were observed at 6 months (322  117 mmol/mol;
P ¼ 0.344), 12 months (340  124 mmol/mol;
P ¼ 0.250), or 24 months (284  119 mmol/mol;
P ¼ 0.466; n ¼ 5) after SRC implantation.
MRI and Renal Scintigraphy
No signiﬁcant changes in renal volume (by MRI) in the
left (216  23 to 207  24 ml) or right (237  28 to 243
 32 ml) kidney were observed 12 months after NKA.
No changes in either cortical thickness (by MRI) or
renal split function (by renal scintigraphy) were
observed 12 months after NKA (Figure 5). The evolu-
tion of S-creatinine and eGFR (cystatin-C) including
historical analyses of S-creatinine and eGFR (cystatin-C)
in the 6 Swedish patients before and after NKA are
shown in Supplementary Figure 1.
Postoperative Complications
Nine serious adverse events (SAEs) were reported
after the laparoscopic surgical procedure (Table 2).
The 24-hour period after kidney cell implantation was
unremarkable in all patients. The postoperative SAEs
during the observation period included fatigue (n ¼ 3),
wound infection (n ¼ 1), pneumonia (n ¼ 1), urinary
tract infection (n ¼ 1), overhydration (n ¼ 1), cecal
volvulus (n ¼ 1), and anastomotic hemorrhage (n ¼ 1).
Although the SAEs were deemed not to be related to
the NKA product in 6 cases, a relation could not be
ruled out in the ﬁrst patient, who experienced fatigue
and pneumonia of unknown etiology in the post-
operative period. However, as bronchioalveolar lavage
did not reveal any renal epithelial cells, a relation to
NKA seems less likely. Detailed descriptions of the
medical history and clinical course following retro-
peritoneoscopic renal cell implantation in each of the 7
patients are presented in the Supplementary Material.
DISCUSSION
The primary aim of this ﬁrst-in-human, phase 1, open-
label study of NKA was to investigate the safety of
laparoscopic implantation of SRCs in the cortex of the
recipient kidney. Although all cell implantations were
uneventful, the rate of postoperative complications was
signiﬁcant in this patient group. Beside fatigue and109
Table 3. Baseline data on renal functions in study patients
Patient
Renal volume
R versus L (ml)a
Cortical thickness
R versus L (mm)a
Split function
R versus L (%)b
GFRc
(ml/min)
eGFRd
(ml/min)
S-creatinine
(mmol/l)
Urea
(mmol/l)
ACR
(mmol/mol)
1 169 versus 144 13 versus 13 55 versus 45 27 34 215 18.5 40
2 237 versus 257 10 versus 10 46 versus 54 39 22 168 17.5 218
3 369 versus 297 27 versus 19 60 versus 40 26 19 261 17.0 248
4 214 versus 231 18 versus 13 47 versus 53 nd 28 192 24.5 409
5 223 versus 175 21 versus 16 60 versus 40 27 25 227 21.8 74
6 208 versus 194 16 versus 17 46 versus 54 15 19 283 22.4 227
7 238 versus 259 nd 51 versus 49 19 23 291 19.3 169
23769 versus 21656 186 versus 153 522 versus 486 26  3 25  2 235  18 20.1  2.8 198  46
ACR, albumincreatinine ratio; eGFR, estimated glomerular ﬁltration rate; GFR, glomerular ﬁltration rate; L, left; ND, not determined; R, right.
Data are mean  SEM.
aBy magnetic resonance imaging.
bBy renal scintigraphy.
cBy iohexol.
dBy cystatin C.
CLINICAL RESEARCH P Stenvinkel et al.: Implantation of Autologous Selected Renal Cellsinfectious complications, a serious case of postoperative
volvulus and subsequent hemicolectomy occurred.
There was no direct correlation with the cell implanta-
tion procedure and the development of a volvulus.
Future trials of renal cell implantation should incorpo-
rate alternative delivery methods, such as percutaneous
image-guided neo-kidney augmentation, of autologous
SCR into the renal cortex as potentially safer alternatives.
Although the study was neither designed nor pow-
ered to study the effects of renal cell implantation on
renal functions, a secondary objective of the protocol
was to study renal functions 12 months after the inter-
vention. We report no statistically signiﬁcant effects of
renal cell implantation on renal volume (MRI), split renal
function (renal scintigraphy), or cortical thickness (MRI)
12 months after renal cell implantation (Figure 5). No
signiﬁcant changes in iohexol clearance, eGFR (cystatin
C), ACR, or S-creatininewere observed at 12months after
implantation (Figure 4). However, extended follow-up to
24 months after SRC implantation demonstrated a
decrease in eGFR (cystatin C), implying that a single
cortical injection of SRCs does not confer long-term
preservation of renal function. None of the patients
had initiated renal replacement therapy at 24 months of
follow-up. Our clinical observation are in agreement
with animal data showing that SCR engraftment in the
treated kidney last up to 6months postimplantation.15,16
One patient died of ischemic heart disease and heart
failure about 30 months after implantation. It has been
reported that direct renal injection of autologous stem
cells resulted in hematuria and masses at the site of in-
jection due to angiomyeloproliferative lesions in a case of
lupus nephritis.25 However, repeat MRIs of the kidney
after the implantation procedure did not reveal any renal
masses at the site of injection or any evidence of scarring
or hemorrhage.
This safety study was not designed to study mecha-
nistic pathways for a putative therapeutic bioactivity of110SRCs. Because SCRs consist of autologous, homologous
cells that are naturally involved in renal repair and
regeneration, it is possible that multiple mechanisms are
active. Diverse paracrine mechanisms may catalyze the
beneﬁts documented in animal models using this cell
population.15,16 Detailed characterization show that the
cell populations are composed of E-cadherin, pancadherin,
cytokeratin 8/18/19, g-glutamyl transpeptidase, and
oxygen-responsive subpopulations.15,16,18 Progressive
ﬁbrosis is a hallmark of diabetic kidney disease,26 and
transforming growth factor b1, plasminogen activator
inhibitor1, and ﬁbronectin may trigger pathologies that
promote tissue inﬂammation and deposition as well as
inadequate degradation of epithelialmesenchymal tran-
sition of tubular epithelial cells.27 Thus, the reduction in
proﬁbrotic markers up to 6 months after implantation of
SRCs15,16,18 may, at least in part, explain the beneﬁcial ef-
fects observed in animal studies. In vitro studies demon-
strate that SRCs are highly chemotactic to factors released
by damaged tubules and that the cells migrate to and
localize in tubules, peritubular space, and damaged
glomeruli.15 Tissue inﬂammation is another prominent
feature of diabetic nephropathy that promotes disease
progression. As SCRs modulated urine CCL/MCP1 and
CCL5/RANTES protein levels, which indicates attenuated
nuclear factorkB response, SCRs may provide additional
immune-modulatory cues to diseased renal tissue.18
Several limitations of this phase 1 safety study
should be considered. As the diagnosis of diabetic ne-
phropathy was made based on clinical history and was
conﬁrmed by renal biopsy in only 1 case (patient 6), we
cannot exclude other or superimposed kidney diseases,
such as nephrosclerosis. We also acknowledge that
potential differences in rat models of progressive dia-
betic nephropathy and human diabetic nephropathy,
especially with regard to disease duration, may play a
role when results from NKA in animal models16 are
compared to results of this “ﬁrst-in-human” study.Kidney International Reports (2016) 1, 105–113
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Figure 4. Changes in (a) S-creatinine, (b) estimated glomerular ﬁltration rate (cystatin-C), (c) glomerular ﬁltration rate (iohexol), and
(d) albumincreatinine ratio during the 24-month observation period following implantation of selected renal cells in the kidney cortex.
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Figure 5. Changes in cortical thickness (by magnetic resonance imaging [MRI]) and split function (by renal scintigraphy) in the 6 Swedish
patients in the study.
CLINICAL RESEARCH P Stenvinkel et al.: Implantation of Autologous Selected Renal CellsAlthough the data show no signiﬁcant progression of
eGFR during the ﬁrst 12 months after kidney cell im-
plantation, the limited number of patients and the
substantial heterogeneity in patterns of kidney func-
tion decline reported in the 2 years before the start of
renal replacement therapy,28 we can draw no ﬁrm
conclusions regarding the effects of NKA on kidney
disease progression during the ﬁrst 12 months. As we
included older, obese, type 2 diabetic CKD patients
(eGFR range 19–34 ml/min), additional studies are
needed to determine whether implantation of SRCs
in younger, non-obese, type 2 diabetic patients
without signiﬁcant comorbidity and better renal
function would result in better outcome. Release of
manufacturing product requires SRCs to be at least
70% viable at time of release, as well as to retain
viability and both phenotypic and functional charac-
teristics for 3 days at 3C. All products implanted in
this study had >90% cell viability at time of release.
No data on renal cell viability after the trans-Atlantic
airplane transport before implantation are available.112Other limitations include lack of data on the extent of
loss of SRCs via the medulla to urine and/or loss to the
bloodstream after implantation. It would have been of
interest to perform a re-biopsy and to evaluate tissue
expression of pro-ﬁbrotic and pro-inﬂammatory
markers after kidney cell implantation, as has been
reported in preclinical studies.18–20 However, beccause
this was a safety study, postimplantation kidney
biopsies were not performed.
Taken together, in this phase 1, ﬁrst-in-human,
2-center SRC implantation study in obese, type 2
diabetic, CKD 3 to 4 patients, we report the 12-month
follow-up and extended data to 24 months after the
procedure. Based on the observation of multiple SAE
after implantation, safer techniques for delivery of
SRC should be considered in future studies in this
vulnerable patient group. As extended 24-month
follow-up in 5 patients showed a decline of eGFR, a
single implantation of SRCs does not appear to pro-
vide beneﬁcial effects on kidney function beyond
1 year.Kidney International Reports (2016) 1, 105–113
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